Chronic Recurrent Multifocal Osteomyelitis (CRMO) is an inflammatory bone disease characterized by sterile osteomyelitis. CRMO is characterized by the presence of multiple and recurrent foci of sterile osteomyelitis, usually involving the metaphysis of long bones, pelvis, clavicle and jaw and mainly affects children and adolescents even though adult forms have been described. The diagnosis requires the presence of consistent clinical imaging and laboratory features. Not rarely, biopsy is needed. CRMO treatment is not standardised, usually first-line approach consist of non- steroidal anti-inflammatory drugs. Second-line treatment implies the use of corticosteroids, bisphosphonates, immunosuppressant and, in selected cases, anti Tumor Necrosis Factor a (TNF-a). We report a case of CRMO in a 24-year-old, semi-professional basketball player. After a partial response to anti-inflammatory treatment, he was administered with i.v. neridronate with a good response and achievement of clinical remission.
A case of adult chronic recurrent multifocal osteomyelitis successfully treated with neridronate
Fassio A;Adami G;Boninsegna, Enrico;Mansueto G;Giollo A;Rossini M;Gatti D
2019-01-01
Abstract
Chronic Recurrent Multifocal Osteomyelitis (CRMO) is an inflammatory bone disease characterized by sterile osteomyelitis. CRMO is characterized by the presence of multiple and recurrent foci of sterile osteomyelitis, usually involving the metaphysis of long bones, pelvis, clavicle and jaw and mainly affects children and adolescents even though adult forms have been described. The diagnosis requires the presence of consistent clinical imaging and laboratory features. Not rarely, biopsy is needed. CRMO treatment is not standardised, usually first-line approach consist of non- steroidal anti-inflammatory drugs. Second-line treatment implies the use of corticosteroids, bisphosphonates, immunosuppressant and, in selected cases, anti Tumor Necrosis Factor a (TNF-a). We report a case of CRMO in a 24-year-old, semi-professional basketball player. After a partial response to anti-inflammatory treatment, he was administered with i.v. neridronate with a good response and achievement of clinical remission.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.